Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 6, 1996 - Issue 5
Submit an article Journal homepage
22
Views
10
CrossRef citations to date
0
Altmetric
Research

Section Review Biologicals & Immunologicals: Advances in antibody engineering

Andrew JT George Department of Immunology, Royal Postgraduate Medical School, Hammersmith Hospital, Du Cane Road, London, W12 ONN, UK
&
Agamemnon A Epenetos Antisoma Ltd., West Africa House, Hanger Lane, Ealing, London, W5 3QR, UK
Pages 441-456 | Published online: 29 Feb 2008

References to Primary Literature

  • KOHLER G, MILSTEIN C: Continuous cultures of fused cells secreting antibody of predefined specificity. Na-ture (1975) 256:495-497. Description of hybridoma technology.
  • HAMBLIN TJ, ABDUL-AHAD AK, GORDON J, STEVENSONFK, STEVENSON GT: Preliminary experience in treating lymphocytic leukaemia with antibody to immuno-globulin idiotypes on the cell surfaces. Br. J. Cancer (1980) 42:495–502.
  • GEORGE AJT, SPOONER RA, EPENETOS AA: Applications of monoclonal antibodies in clinical oncology. Immu-nol. Today (1994) 15:559–561.
  • RIETHMULLER G, SCHNEIDER-GADUCKE E, SCHLIMOK G, SCHMIEGEL W, RAAB R, HOFFKEN K, GRUBER R, PICHL-MAIER H, HIRCHE H, PICHLMAYR R et al.: Randomised trial of monoclonal antibody for adjuvant therapy of resected Duke's C colorectal carcinoma. Lancet (1994) 343:1177-1183. Therapeutic benefit of monoclonal antibody therapy seen in adjuvant setting.
  • HIRD V, MARAVEYAS A, SNOOK D, DHOKIA B, SOUTTER WP, MEARES C, STEWART JS, MASON P, LAMBERT HE, EPENETOS AA: Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br. J. Cancer (1993) 68:403-406. Preliminary but highly promising trial of radioimmunotherapy.
  • ELLIOTT MJ, MAINI RN, FELDMANN M, KALDEN JR, ANTONI C, SMOLEN JS, LEEB B, BREEDVELD FC, MACFARLANE JD, BIJL H et al.: Randomised double-blind comparison of chimeric monoclonal antibody to tu-mour necrosis factor a (cA2) versus placebo in rheuma-toid arthritis. Lancet (1994) 344:1105-10. Antibody against a cytokine proves effective for rheumatoid arthritis.
  • HALE G, DYER MJ, CLARK MR, PHILLIPS JM, MARCUS R, RIECHMANN L, WINTER G, WALDMANN H: Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATI1-1H. Lancet (1988) 11:1394–1399.
  • ISAACS JD, WATTS RA, HAZLEMAN BL, HALE G, KEOGAN MT, COBBOLD SP, WALDMANN H: Humanised mono-clonal antibody therapy for rheumatoid arthritis. Lancet (1992) 340:748–752.
  • BOSTROM L, RINGDEN 0: Monoclonal antibodies in transplantation: prophylaxis and treatment of graft-versus-host disease after bone marrow transplantation. In: Monoclonal antibodies. Production, engineering and clinical application. Ritter MA & Ladyman HM (Eds.), Cam-bridge University Press, Cambridge (1995):317–339.
  • GIRAL M, DANTAL J, CANTAROVICH D, HOURMANT M, BAATARD R, LE MAUFF B, JACQUES Y, SOULLLLOU JP: Monoclonal antibodies in transplantation: use as thera-peutic agents in clinical organ transplantation. In: Monoclonal antibodies. Production, engineering and clinical application. Ritter MA & Ladyman HM (Eds.), Cambridge University Press, Cambridge (1995):340–361.
  • COHEN J: Monoclonal antibodies in infectious disease: prophylaxis and therapy. In: Monoclonal antibodies. Pro-duction, engineering and clinical application. Ritter MA & Ladyman HM (Eds.), Cambridge University Press, Cambridge (1995):260–273.
  • PRESS OW, FARY JF, APPELBAUM FR, MARTIN PJ, BADGER CC, NELP WB, GLENN S, BUTCHKO G, FISHER D, PORTER B et al.: Radiolabeled-antibody therapy of B-cell lym-phoma with autologous bone marrow support. N. Engl. J. Med. (1993) 329:1219-1224. Perhaps, the most exciting application of monoclonal antibodies to the treatment of bulky neoplastic disease.
  • ORLANDI R, GUSSOW DH, JONES PT, WINTER G: Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA (1989) 86:3833-3837. First description of PCR amlification of immunoglobulin V region domains.
  • MARKS JD, TRISTEM M, KARPAS A, WINTER G: Oligonudeotide primers for polymerase chain reaction ampli-fication of human immunoglobulin variable genes and design of family-specific oligonudeotide probes. Eur. J. Immunol. (1991) 21:985-991. Description of primers to PCR amplify human V region genes.
  • SASTRY L, ALTING-MEES M, HUSE WD, SHORT JM, SORGE JA, HAY BN, JANDA KD, BENKOVIC SJ, LERNER RA: Clon-ing of the immunological repertoire in Escherichia coil for generation of monoclonal catalytic antibodies: con-struction of a heavy chain variable region-specific cDNA library. Proc. Natl. Acad. Sci. USA (1989) 86:5728–5732.
  • LARRICK JVI, FRY RE: PCR amplification of antibody genes. Methods: A Companion to Methods in Enzymology (1991) 2:106–110.
  • DOBEL S, BREITLING F, SEEHAUS T, LITTLE M: Generation of a human IgM expression library in E. coli. Methods in Molecular and Cellular Biology (1992) 3:47–52.
  • NICHOLLS PJ, JOHNSON VG, BLANFORD MD, ANDREW SM: An improved method for generating single-chain antibodies from hybridomas. J. Immunol. Meth (1993) 165:81–91.
  • WARD VK, SCHNEIDER PG, KREISSIG SB, HAMMOCK BD, CHOUDARY PV: Cloning, sequencing and expression of the Fab fragment of a monoclonal antibody to the herbicide atrazine. Protein Eng. (1993) 6:981–988.
  • GE L, KNAPPIK A, PACK P, FREUND C, PLÜCKTHUN A: Expressing antibodies in Escberichia coli. In: Antibody Engineering: A Practical Approach, 2nd edition. Borrebaeck C (Ed.), Oxford University Press, Oxford (1995):229–266.
  • HUSTON JS, GEORGE AJT, TAI M-S, MCCARTNEY JE, JIN D, SEGAL DM, KECK P, OPPERMAN H: Single-chain Fv design and production by preparative folding. In: Antibody Engineering: A Practical Approach, 2nd edition. Borrebaeck C (Ed.), Oxford University Press, Oxford (1999:185–225.
  • MORRISON SL, COLOMA MJ, ESPINOZA D, HASTINGS A, SHIN S-L, WIMS LA, WRIGHT A: Vectors and approaches for the eulcaryotic expression of antibodies and anti-body fusion proteins. In: Antibody Engineering: A Practi-cal Approach, 2nd edition. Borrebaeck C (Ed.), Oxford University Press, Oxford (1995):267–293.
  • BE 1ER M, CHANG CP, ROBINSON RR, HORWITZ AH: Eschetichia colt secretion of an active chimeric anti-body fragment. Science (1988) 240:1041–1043.
  • SKERRA A, PLÜCKTHUN A: Assembly of a functional inununoglobulin fv fragment in Escherichia coll. Sci-ence (1988) 240:1038-1041. References 23 and 24 are the first decription of expression of antibody fragments in bacteria, a vital step in their exploitation.
  • HORWITZ AH, CHANG CP, BETTER M, HELLSTROM KE, ROBINSON RR: Secretion of Functional Antibody and Fab Fragment from Yeast Cells. Proc. Natl. Acad. Sci. USA (1988) 85:8678–8682.
  • HASESMANN CA, CAPRA JD: High-level production of afunctional imtnunog,lobulin heterodimer in a bacu-lovirus expression system. Proc. Natl. Acad, Sci. USA (1990) 87:3942–3946.
  • BEI R, SCHLOM J, KASHMIRI SV: Baculovirus expression of a functional single-chain immunog,lobulin and its IL-2 fusion protein. J. Immunol. Meth. (1995) 186:245–255.
  • DORAI H, MCCARTNEY JE, HUDZIAK RM, TAI M-S, LAMINET AA, HOUSTON LL, HUSTON JS, OPPERMANN Fl: Mammalian cell expression of single-chain Fv (sFv) antibody proteins and their C-terminal fusions with Interleukin-2 and other effector domains. Bio/technol-ogy (1994) 12:890–897.
  • JOST CR, KURUCZ I, JACOBUS CM, TITUS JA, GEORGE AJT, SEGAL DM: Mammalian expression and secretion of functional single-chain Fv molecules. J. Biol. Chem. (1994) 269:26267–26273.
  • CARTER P, KELLY RF, RODRIGUES ML, SNEDECOR B, COVARRUBIAS M, VELLIGAN MD, WONG WLT, ROWLAND AM, KOITS CE, CARVER ME etal.: High level Escberichia Coil expression and production of a bivalent human-ized antibody fragment. Bio/technology (1992) 10:163–167.
  • GEORGE AJT, Trrus JA, JOST CR, KURUCZ I, PEREZ P, ANDREW SM, NICHOLLS PJ, HUSTON JS, SEGAL DM: Redi-rection of T cell-mediated cytotoxicity by a recombinant single-chain Fv molecule. J. Immunol. (1994) 152:1802-1811. As well as describing a targeting strategy using sFy, this paper outlines a useful and simple method for refolding sFy from the periplasm of bacteria.
  • NICHOLLS PJ, JOHNSON VG, ANDREW SM, HOOGEN-BOOM HR, RAUS JC, YOULE RJ: Characterization of single-chain antibody (sFv)-toxin fusion proteins pro-duced in vitro in rabbit reticulocyte lysate. J. Biol. Chem. (1993) 268:5302–5308.
  • HIATT A, CAFFERKEY R, BOWDISH K: Production of antibodies in transgenic plants. Nature (1989) 342:76–78.
  • WHITELAM GC, COCKBURN W, OWEN MR: Antibody production in transgenic plants. Biochem. Soc. Trans. (1994) 22:940–944.
  • COURTENAY-LUCK NS, EPENETOS AA, WINEARLS CG, RI 11 ER MA: Pre-existing human anti-murine inununo-globulin reactivity due to polyclonal rheumatoid fac-tors. Cancer Res. (1987) 47:4520–4525.
  • COLTRTENAY-LUCK NS, EPENETOS AA, SIVOLAPENKO GB,LARCHE M, BARKANS JR, RITTER MA: Development of anti-idiotypic antibodies against tumour antigens and autoantigens in ovarian cancer patients treated hi- traperitoneally with mouse monoclonal antibodies. Lancet (1988) 11:894–897.
  • SA'ADU A, ZUMLA A: Human monoclonal antibodies: production, use, problems. In: Monoclonal antibodies. Production, engineering and clinical application. Ritter MA 8z Ladyman HM (Eds.), Cambridge University Press, Cam-bridge (1995) :85–120.
  • BOULIANNE GL, HOZUMI N, SI IULMAN MJ: Production of functional chimaeric mouse/human antibody. Nature (1984) 312:643–646.
  • MORRISON SL, JOHNSON MJ, HERZENBERG LA, CM VT:Chitneric human antibody molecules: mouse antigen-binding domains with human constant region do-mains. Proc. Natl. Acad. Sci. USA (1984) 81:6851–6855.
  • NEUBERGER MS, WILLIAMS GT, MITCHELL EB, JOUHAL SS,FLANAGAN JG, RABBITTS TH: A hapten-specific chi-maeric IgE antibody with human physiological effector function. Nature (1985) 314:268–270.
  • KHAZAELI MB, CONRY RM, LOBUGLIO AF: Human im-mune response to monoclonal antibodies. J. Immuno-ther. (1994) 15:42–52.
  • JONES PT, DEAR PH, FOOTE J, NEUBERGER MS, WINTERG: Replacing the complementarity-determining re-gions in a human antibody with those from a mouse. Nature (1986) 321:522–525.
  • REICHMANN L, CLARK M, WALDMANN H, WINTER G: Reshaping human antibodies for therapy. Nature (1988)322:323-327. Description of the humanisation of CAMPATH–1.
  • GÜSSOW D, SEEMANN G: Humanization of monoclonal antibodies. Meth. Enzymol. (1991) 203:99–121.
  • FOOTE J, WINTER G: Antibody framework residues affecting the conformation of the hypervariable loops. J. Mol. Biol. (1992) 224:487–499.
  • PADLAN EA: A possible procedure for reducing the immtmogenicity of antibody variable domains while preserving their ligand-binding properties. Mo/. Immu-not (1991) 28:489-498. Ouline of the process by which antibodies might be veneered or resurfaced.
  • PEDERSEN JT, HENRY AH, SEARLE SJ, GUILD BC, ROGUSKAM, REES AR: Comparison of surface accessible residues In human and murine inununoglobulin Fv domains. Implication for humanization of murine antibodies. J. Mol. Biol. (1994) 235:959–973.
  • ROGUSKA MA, PEDERSEN JT, KEDDY CA, HENRY All, SEARLE SJ, LAMBERT JM, GOLDMACHER VS, BLATTLER WA, REES AR, GUILD BC: Humanization of murine mono-clonal antibodies through variable domain resurfacing. Proc. Natl. Acad. Sci. USA (1994) 91:969–973.
  • MAINI RN, ELLIOT!' MJ, BRENNAN FM, WILLIAMS RO, CHUCQ, PALEOLOG E, CHARLES PJ, TAYLOR PC, FELDMANN M: Monoclonal anti-TNFec antibody as a probe of patho-genesis and therapy of rheumatoid disease. Immunol. Rev. (1995) 144:195–223.
  • BIRD RE, HARDMAN ICD, JACOBSON JW, JOHNSON S, KAUFMAN BM, LEE SM, LEE T, POPE SH, RIORDAN GS,WHITLOW M: Single-chain antigen-binding proteins. Science (1988) 242:423–426.
  • IIUSTON JS, LEVINSON D, MUDGETT-HUNTER M, TAI M-S, NOVOTNY J, MARGOLIES MJ, RIDGE RJ, BRUCCOLERI RE,HABER E, CREA R et al.: Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Es-cbericbia coll. Proc. Natl. Acad. Sci. USA (1988) 85:5879-5883. Papers 50 and 51 are the first descriptions of the sEv molecule.
  • PANTOLIANO MW, BIRD RE, JOHNSON S, ASEL ED, DODDSW, WOOD JF, HARDMAN KD: Conformational stability, folding, and ligand-binding affinity of single-chain Fv immunoglobulin fragments expressed in Escbericbia colt. Biochem. (1991) 30:10117–10125.
  • WHITLOW M, BELL BA, FENG SL, FILPULA D, HARDMANK.D, HUBERT SL, ROLLENCE ML, WOOD JF, SCHOTT ME, MILENIC DE et at: An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng. (1993) 6:989–995.
  • DESPLANCQ D, KING DJ, LAWSON AD, MOUNTAIN A: Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3. Protein Eng. (1994) 7:1027–1033.
  • TURNER DJ, RITTER MA, GEORGE AJT: Importance of the linker in expression of single-chain Fv antibody frag-ments: optimisation of peptide sequence using phage display technology. Submitted for publication (1996).
  • GLOCKSHUBER R, MALTA M, PFITZINGER I, PLÜCKTHUN A: A comparison of strategies to stabilize immunoglobu-lbt Fv-fragments. Biochem. (1990) 29:1362-1367. Biochemical characterisation of a number of Fv-based molecules, including the dsFy
  • BRINKMANN U, REITER Y, JUNG SH, LEE B, PASTAN I: A recombinant immunotoxin containing a disulfide-sta-bilized Fv fragment. Proc. Natl. Acad. Sci. USA (1993) 90:7538–7542.
  • REITER Y, BRINKMANN U, JUNG SH, LEE B, KASPRZYK PG,KING CR, PASTAN I: Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. J. Biol. Chem. (1994) 269:18327–18331.
  • REITER Y, BRINKMANN U, KREITMAN RJ, JUNG SH, LEE B,PASTAN I: Stabilization of the Fv fragments in recombi-nant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochem. (1994) 33:5451–5459.
  • REITER Y, PAI LH, BRINKMANN U, WANG QC, PASTAN I:Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-sta-bilized Fv fragment Cancer Res. (1994) 54:2714–2718.
  • WEBBER KO, REITER Y, BRINKMANN U, KREITMAN R, PASTAN I: Preparation and characterization of a disul-fide-stabilized Fv fragment of the anti-Tac antibody: comparison with its single-chain analog. Mol. Immunol. (1995) 32:249–258.
  • STANFIELD RI., TAKIMOTO-KAMIMURA M, RINI JM, PROFYAT, WILSON IA: Major antigen-induced domain rear-rangements in an antibody. Structure (1993) 1:83–93.
  • HUSTON JS, MCCARTNEY J, TAI MS, MOTTOLA-HART-SHORN C, JIN D, WARREN F, KECK P, OPPERMANN H: Medical applications of single-chain antibodies. Int. Rev. Immunot (1993) 10:195–217.
  • HUSTON JS, GEORGE AJT, ADAMS GP, STAFFORD WF JAMAR F, TAI M-S, MCCARTNEY JE, OPPERMANN II, HEELAN BT, PETERS AM et at: Single-chain Fv radioim-munotargeting. Quarterly Journal of Nuclear Medicine (1996) in press.
  • COLCIIER D, BIRD R, ROSELLI M, HARDMAN KD, JOHNSON 5, POPE S, DODD SW, PANTOLIANO MW, MILENIC DE, SCI ILOM J: In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J. Natl. CancerInst. (1990) 82:1191–1197.
  • YOKOTA T, MILENIC DE, WHITLOW M, SCHLOM J: Rapid tumor penetration of a single-chain Fv and comparison with other inununoglobulin forms. Cancer Res. (1992) 52:3402-3408. Demonstration of improved penetration of sEv in comparison with larger antibody fragments.
  • YOKOTA T, MILENIC DE, WHITLOW M, WOOD JF, HUBERT SL, SCHLOM J: Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other inununoglobulin forms. Cancer Res. (1993) 53:3776–3783.
  • GEORGE AJT, HUSTON JS, HABER E: Exploring and exploiting the antibody and Ig superfamily combining sites. Nature Biotechnology (1996) in press.
  • WARD ES, GOSSOW D, GRIFFITHS AD, JONES PT, WINTERG: Binding activity of a repertoire of single hninuno-globulin variable domains secreted from Esberkbia coli. Nature (1989) 341:544-546. First description of dAbs.
  • HAMERS-CASTERMAN C, ATARHOUCH T, MUYLDERMANS S, ROBINSON G, HAMERS C, SONGA EB, BENDAHMAN N, HAMERS R: Naturally occurring antibodies devoid of light chains. Nature (1993) 363:446–448.
  • DAVIES J, RIECHMANN L: `Camelising' human antibody fragments: NMR studies on VII domains. FEBS Lett. (1994) 339.285–290.
  • PESSI A, BIANCHI E, CRAMERI A, VENTURINI S, TRAMON-TANO A, SOLLAZZO M: A designed metal-binding pro-tein with a novel fold. Nature (1993) 362:367–369.
  • MARTIN F, TONIATTI C, SALVATI AL, VENTURINI 5, CILIBERTO G, CORTESE R, SOLLAZZO M: The affinity-se-lection of a minibody polypeptide inhibitor of human interleukin-6. EMBOJ. (1994) 13:5303–5309.
  • KU J, SCHULTZ PG: Alternate protein frameworks for molecular recognition. Proc. Natl. Acad. Sci. USA (1995) 92:6552–6556.
  • DUNCAN AR, WINTER G: The binding site for Clq on IgG.Nature (1988) 332:738–740.
  • DUNCAN AR, WOOF JM, PARTRIDGE LJ, BURTON DR, WINTER G: Localization of the binding site for the human high-affinity Fe receptor on IgG. Nature (1988) 332:563–564.
  • SKERRA A, PFITZINGER I, PLÜCKTHUN A: The functional expresssion of antibody Fv fragments in Eschericbia coil: improved vectors and a generally applicable puri-fication technique. Bio/technology (1991) 9:273–278.
  • GEORGE AJT, JAMAR F, TAI M-S, HEELAN BT, ADAMS GP, MCCARTNEY JE, HOUSTON LL, WEINER LM, OPERMANNII, PETERS AM et al.: Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cyste-inyl peptide. Proc. Natl. Acad. Sci. USA (1995) 92:8358-8363. Incorporation of a short peptide to allow site-specific facile labelling of recombinant molecules with radiometals.
  • NEUBERGER MS, WILLIAMS GT, FOX RO: Recombinantantibodies possessing novel effector functions. Nature (1984) 312:604-608. First antibody fusion proteins.
  • CHAUDHARY VK, QUEEN C, JUNGHANS RP, WALDMANN TA, FITZGERALD DJ, PASTAN I: A recombinant immuno-toxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature (1989) 339:394-397. The first sFv-based fusion protein incorporating a potential thera-peutic agent.
  • TAI MS, MUDGETT-HUNTER M, LEVINSON D, WU GM, HABER E, OPPERMANN H, HUSTON JS: A bifunctional fusion protein containing Fe-binding fragment B of staphylococcal protein A amino terminal to antidigoxin single-chain Fv. Biochem. (1990) 29:8024–8030.
  • GANDECHA AR, OWEN MR, COCKBURN B, WHITELAM GC: Production and secretion of a bifunctional staphylococ-cal protein A:: antiphytochrome single-chain Fv fusion protein in Escberkbia colt. Gene (1992) 122:361–365.
  • ESHHAR Z, WAKS T, GROSS G, SCHINDLER DG: Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the y or C subunits of the immu-noglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA (1993) 90:720–724.
  • DAS C, KULKARNI PV, CONSTANTINESCU A, ANTICH P, BLATTNER FR, TUCKER PW: Recombinant antibody-met-allothionein: design and evaluation for radioimmunoi-maging. Proc. Natl. Acad. Sci. USA (1992) 89:9749–9753.
  • SAWYER JR, TUCKER PW, THATTNER FR: Metal-binding chimeric antibodies expressed in Escbericbia colt. Proc. Natl. Acad. Sci. USA (1992) 89:9754–9758.
  • SAVAGE P, SO A, SPOONER RA, EPENETOS AA: A recom-binant single chain antibody interleukin-2 fusion pro-tein. Br. J. Cancer (1993) 67:304–310.
  • BOLETI E, DEONARAIN M, SPOONER RA, SMITH AJ, EPENE-TOS AA, GEORGE AJT: Construction, expression and characterization of a single-chain anti-tumour anti-body-ill-2 fusion protein. Annals of Oncology (1995) 6:945–947.
  • TRAUNECKER A, LANZAVECCHIA A, KARJALAINEN K: Bis-pecific single chain molecules (Janusins) target cyto-toxic lymphocytes on HIV infected cells. EMBO J. (1991) 10:3655–3659.
  • HOLVOET P, LAROCHE Y, LUNEN HR, CAUWENBERGE RV,DEMARSIN E, BROUWERS E, MATTHYSSENS G, COLLEN D: Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dirner-specific antibody and a trun-cated single-chain urokinase. J. Biol. Chem. (1991) 266:19717–19724.
  • YANG WP, GOLDSTEIN J, PROCYK R, MATSUEDA GR,SHAW SY: Design and evaluation of a thrombin-ac-dyable plasminogen activator. Biochem. (1994) 33:606–612.
  • BOSSLET K, CZECH J, LORENZ P, SEDLACEK HII, SCHUER-MANN M, SEEMANN G: Molecular and functional charac-terisation of a fusion protein suited for tumour specific prodrug activation. Br. J. Cancer (1992) 65:234–238.
  • GOSHORN SC, SVENSSON HP, KERR DE, SOMERVILLE JE, SENTER PD, FELL HP: Genetic construction, expression, and characterization of a single chain anti-carcinoma antibody fused to 13-lactamase. Cancer Res. (1993) 53:2123–2127.
  • RODRIGUES ML, PRESTA LG, KOTTS CE, WIRTH C, MOR-DENTI J, OSAKA G, WONG WL, NUIJENS A, BLACKBURN B, CARTER P: Development of a humanized disulfide-sta-bilized anti-p185HER2 Fv-P-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. Cancer Res. (1995) 55:63–70.
  • KOHL J, RUKER F, HIMMLER G, RAZAZZI E, KATINGER H:Cloning and expression of an MV-1 specific single-chain Fv region fused to Escbericbta colt alkaline phosphatase. Ann. NY Acad. Sci. (1991) 646:106–114.
  • WELS W, HARWERTFI I-M, ZWICKL M, HARDMAN N, GRONER B, HYNES NE: Construction, bacterial expres-sion and characterization of a bifunctional single-chain antibody-phosphatase fusion protein targeted to the human ER13B-2 receptor. Bio/technology (1992) 10:1128–1132.
  • NERI D, DE LALLA C, PETRUL H, NERI P. WINTER G: Calmodulin as a versatile tag for antibody fragments. Bio/technology (1995) 13:373–377.
  • DÜBEL S, BREITLING F, KONTERMANN R, SCHMIDT T, SKERRA A, LITTLE M: Bifunctional and mukimeric com-plexes of streptavidin fused to single chain antibodies (scFv). J. Immunol. Meth. (1995) 178:201–209.
  • GEORGE AJT: Bispecific antibodies in tumour therapy. Tumor Targeting (1995) 1:185–187.
  • SNIDER DP, SEGAL DM: Efficiency of antigen presenta-tion after antigen targeting to surface IgD, IgM, MHC, FeyRII, and B220 molecules on murine splenic B cells. J. Immunol. (1989) 143:59–65.
  • MILSTEIN C, CUELLO AC: Hybrid hybridomas and their use in immunohistochemistry. Nature (1983) 305:537–540.
  • ADAMS GP, MCCARTNEY JE, TAI MS, OPPERMANN H, HUSTON JS, STAFFORD III WF, BOOKMAN MA, FAND I, HOUSTON LL, WEINER LM: Highly specific in vivo tumor targeting by monovalent and divalent forms of 741E8 anti-c-erbB-2 single-chain Fv. Cancer Res. (1993) 53:4026-4034. Demonstration of the advantage of bivalency in tumour targeting.
  • Cumber AJ, Ward ES, Winter G, Pamell GD, Wawrzynczak EJ: Comparitive stabilities in vitro and in vivo of a recombinant mouse antibody FvCys fragment and a bisFvCys conjugate. J. Immunol. (1992) 149:120–126.
  • PACK P, PLOCKTHUN A: Miniantlbodies: use of amphipathic helices to produce functional, flexibly linked dimeric Fv fragments with high avidity in Escbericbia coll. Biochem. (1992) 31:1579–1584.
  • KOSTELNY SA, COLE MS, TS0 JY: Formation of a bispedfic antibody by the use of leudne zippers. J. Immunol. (1992) 148:1547-1553. Papers 103 and 104 describe the dimerisation of antibodies by fusion with amphilic helices.
  • GRUBER M, SCHODIN BA, WILSON ER, KRANZ DM: Effi-cient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coil. J. Immu-nol. (1994) 152:5368–5374.
  • IIAYDEN MS, LINSLEY PS, GAYLE MA, BAJORATH J, BRADY WA, NORRIS NA, FELL HP, LEDBETTER JA, GILLILAND LK: Single-chain mono- and bi-specific antibody derivatives with novel biological properties and antitumour activ-ity from a COS cell transient expression system. Thera-peutic Immunol. (1994) 1:3–15.
  • MALLENDER WD, VOSS E JR.: Construction, expression, and activity of a bivalent bispecific single-chain anti-body. J. Biol. Chem. (1994) 269:199–206.
  • KURUCZ I, TITUS JA, JOST CR, JACOBUS CM, SEGAL DM: Retargeting of Cll. by an efficiently refolded bispecific single-chain Fv ditner produced in bacteria. J. Immunol. (1995) 154: 4576–4582.
  • NERI D, MOMO M, PROSPERO T, WINTER G: High-affinity antigen binding by chelating recombinant antibodies(CRAbs). J. Mol. Biol. (1995) 246: 367–373. Bispecific antibodies can be created that show greatly enhanced functional affinity for their antigen.
  • HOLLINGER P, PROSPERO T, WINTER G: `Diabodies': small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA (1993) 90: 6444–6448. Description of diabodies.
  • 'WHITLOW M, FILPULA D, ROLLENCE ML, FENG SL, WOOD JF: Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv. Protein Eng. (1994) 7: 1017–1026.
  • WINTER G, GRIFFITHS AD, HAWKINS RE, HOOGENBOOM FIR: Making antibodies by phage display technology. Annu. Rev. Immunol. (1994) 12: 433–455.
  • MODEL P, RUSSEL M: Filamentous bacteriophage. In: The Bacteriophages, vol. 2. Calendar R (Ed.), Plenum Press, New York (1988):375–456.
  • SAMBROOK J, FRITSCH EF, MANIATIS T (1989). Molecular Cloning: a Laboratory ManuaL New York, Cold Spring Harbor Laboratory Press.
  • SMITH GP: Filamentous fusion phage: novel expression vectors that display cloned antigens on the virionsurface. Science (1985) 228:1315-1317. Expression of peptides on phage, a precursor to the expression of antbody fragments.
  • SCOTT JK, SMITH GP: Searching for peptide ligands with an epitope library. Science (1990) 249: 386–390.
  • MCCAFFERTY J, GRIFFITHS AD, WINTER G, CHISWELL DJ: Phage antibodies: filamentous phage displaying anti-body variable domains. Nature (1990) 348: 552–554. First description of the expression of antibody fragments on the surface of phage.
  • CLACKSON T, HOOGENBOOM FIR, GRIFFITHS AD, WIN- ▪TER G: Making Antibody Fragments Using Phage Dis-play Libraries. Nature (1991) 352: 624–628. First use of a phage display library to isolate novel antibodies.
  • BARBAS CF III, RANG AS, LERNER RA, BENKOVIC SJ: Assembly of combinatorial antibody libraries on phage surfaces: the gene HI site. Proc. Natl. Acad. Sci. USA (1991) 88: 7978–7982.
  • MARKS JD, HOOGENBOOM HR, BONNERT TP, MCCAF-FERTY J, GRIFFITHS AD, WINTER G: By-passing immuni-zation. Human antibodies from V-gene libraries displayed in phage. J. Mol. Biol. (1991) 222: 581–597.
  • MARKS JD, OUWEHAND WH, BYE JM, FINNERN R, GORICK BD, VOAK D, THORPE SJ, HUGHES JONES NC, WINTER G: Human antibody fragments specific for human blood group antigens from a phage display library. Bio/tech-nology (1993) 11:1145–1149.
  • DE-KRUIF J, TERSTAPPEN L, BOEL E, LOGTENBERG T: Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage anti- body library. Proc. Natl. Acad. Sci. USA (1995) 92:3938-3942. Use of cell sorting techniques to isolate phage binding to cell surfaces.
  • HAWKINS RE, RUSSELL SJ, WINTER G: Selection of phage antibodies by binding affinity. Mimicking affinity matu-ration. J. Mol. Biol. (1992) 226:889–896.
  • BURTON DR, BARBAS CF III, PERSSON MA, KOENIG S, CHANOCK RM, LERNER RA: A large array of human monoclonal antibodies to type 1 human immunodefi-ciency virus from combinatorial libraries of asympto-matic seropositive individuals. Proc. Natl. Acad. Sci. USA (1991) 88:10134-10137. Isolation of antibodies specific for cross reactive determinants on HIV, using phage display.
  • ZEBEDEE SL, BARBAS CF Ill, HOM YL, CAOTHIEN RH, GRAFF R, DEGRAW J, PYATI J, LAPOLLA R, BURTON DR, LERNER RA et al.: Human combinatorial antibody librar-ies to hepatitis B surface antigen. Proc. Natl. Acad. Sci. USA (1992) 89:3175–3179.
  • HEXHAM JM, PARTRIDGE LJ, FURMANIAK J, PETERSEN VB, COLLS JC, PEGG C, REES-SMITH B, BURTON DR: Cloning and characterisation of TPO autoantibodies using com-binatorial phage display libraries. Autoimmunity (1994) 17:167–179.
  • GRAM H, MARCONI LA, BARBAS CF III, COLIET TA, LERNER RA, RANG AS: In vitro selection and affinity maturation of antibodies from a naive combinatorial immuno-globulin library. Proc. Natl. Acad. Sci. USA (1992) 89:3576–3580.
  • DAVIES EL, SMITH JS, BIRKETr CR, MANSER JM, ANDER-SON-DEAR DV, YOUNG JR: Selection of specific phage-display antibodies using libraries derived from chicken immunoglobulin genes. J. Immunol Meth. (1995) 186:125–135.
  • BARBAS CF III, BAIN JD, HOEKSTRA DM, LERNER RA: Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem. Proc. Natl. Acad. Sci. USA (1992) 89:4457–4461.
  • HOOGENBOOM HR, WINTER G: By-passing immunisa-tion. Human antibodies from synthetic repertoires of germline VI; gene segments rearranged in vitro. J. Mol. Biol. (1992) 227:381–388.
  • GRIFFITHS AD, WILLIAMS SC, HARTLEY 0, TOMLINSON II\4, WATERHOUSE P, CROSBY WL, KONTERMANN RE, JONES PT, LOW NM, ALLISON TJ et al.: Isolation of high affinity antibodies directly from large synthetic librar-ies. EMBO J. (1994) 13:3245–3260.
  • NISSIM A, HOOGENBOOM HR, TOMLINSON IM, FLYNN G, MIDGLEY C, LANE D, WINTER G: Antibody fragments from a 'single pot' phage display library as inununo-chemical reagents. EMBO J. (1994) 13:692–698.
  • BRINKMANN U, CHOWDHURY PS, ROSCOE DM, PASTAN I: Phage display of disulfide-stabilized Fv fragments. J. Immunol. Meth. (1995) 182:41–50.
  • GARRAD LS, YANG M, O'CONNELL MP, KELLEY RF, HEN-NER DJ FAB assembly and enrichment in a monovalent phage display system. Bio/technology (1991) 9:1373–1377.
  • HOOGENBOOM HR, GRIFFITHS AD, JOHNSON KS, CHISWELL DJ, HUDSON P, WINTER G: Multi-subunit pro-teins on the surface of filamentous phage: methodolo-gies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res. (1991) 19:4133–4137.
  • KANG AS, BARBAS CF, JANDA KD, BENKOVIC SJ, LERNER RA: Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces. Proc. Natl. Acad. Sci. USA (1991) 88:4363–4366.
  • HERMES JD, PAREKH SM, BLACKLOW SC, KOSTER H, KNOWLES JR: A reliable method for random muta-tagenesis: the generation of mutant libraries using spiked oligodeoxyribonucleotide primers. Gene (1989) 84:143–151.
  • SCHAAPER RM: Mechanisms of mutagenesis in the Es-cbericbia Coli mutator mutDS: role of DNA mismatch repair. Proc. Natl. Acad. Sci. USA (1988) 85:8126–8130.
  • BARBAS CF III, HU D, DUNLOP N, SAWYER L, CABABA D, HENDRY RM, NARA PL, BURTON DR: In vitro evolution of a neutralizing human antibody to human immunode-ficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc. Natl. Acad. Sci. USA (1994) 91:3809-3813. A good example of in vitro affinity maturation of an antibody.
  • ICANG AS, JONES TM, BURTON DR: Antibody redesign by chain shuffling from random combinatorial imrnuno-globulin libraries. Proc. Natl. Acad. Sci. USA (1991) 88:11120–11123.
  • MARKS JD, GRIFFITHS AD, MALMQVIST M, CLACKSON TP, BYE JM, WINTER G: By-passing immunization: building high affinity human antibodies by chain shuffling Bio/technology (1992) 10:779–783.
  • GRIFFITHS AD, WILLIAMS SC, HARTLEY 0, TOMLINSON IM, WATERHOUSE P. CROSBY WE, KONTERMANN RE,JONES PT, LOW NM, ALLISON TJ et al.: Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. (1994) 13:3245-3260. Isolation of high affinity antibodies directly from large phage dispay libraries.
  • PICKER LJ, SLEGELMAN MH: Lymphoid tissues and or-gans. In: Fundamental Immunology, 3rd edition. Paul WE (Ed.), Raven Press, New York (1993):145–197.
  • DITZEL HJ, BINLEY JM, MOORE JP, SODROSKI J, SULLIVAN N, SAWYER LS, HENDRY RM, YANG WP, BARBAS CF III, BURTON DR: Neutralizing recombinant human antibod-ies to a conformational V2- and CD4-binding site-sensi-tive epitope of HIV-1 gp12 0 isolated by using an epitope-masking procedure. J. Immunol. (1995) 154:893–906.
  • MEULEMANS EV, SLOBBE R, WASTERVAL P, RAMAEKERS FC, VAN-EYS GJ: Selection of phage-displayed antibodies specific for a cytoskeletal antigen by competitive elu-tion with a monoclonal antibody. J. Mol. Biol. (1994) 244:353–360.
  • GRIFFITHS AD, MALMQVIST M, MARKS JD, BYE JM, EM-BLETON MJ, MCCAFFERTY J, BAIER M, HOLLIGER ICP, GORICK BD, HUGHES-JONES NC et al.: Human anti-self antibodies with high specificity from phage display libraries. EMBO J. (1993) 12:725–734.

References to Patent Literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.